Dithiolethione compounds inhibit Akt signaling in human breast and lung cancer cells by increasing PP2A activity.
The chemopreventative effects of dithiolethione compounds are attributed to their activation of antioxidant response elements (AREs) by reacting with the Nrf2/Keap1 protein complex. In this study, we show antiproliferative effects of the dithiolethione compound ACS-1 in human cancer cell lines (A549 and MDA-MB-231) by increasing the activity of the tumor suppressor protein phoshatase 2A (PP2A). ACS-1 inhibited epidermal growth factor (EGF)-induced cellular proliferation in a concentration- and time-dependent manner. Akt activation, as determined by serine-473 phosphorylation, was inhibited by ACS-1 in cells stimulated with either EGF or fibronectin. Furthermore, ACS-1 inhibited mammalian target of rapamycin signaling and decreased c-myc protein levels. ACS-1 did not proximally alter EGF receptor or integrin signaling, but caused a concentration-dependent increase in PP2A activity. The effect of ACS-1 on Akt activation was not observed in the presence of the PP2A inhibitor okadaic acid. ACS-1 effects on PP2A activity were independent of ARE activation and cAMP formation. In addition to ACS-1, other dithiolethione compounds showed similar effects in reducing Akt activation, suggesting that this class of compounds may have other effects beyond chemoprevention.
Switzer
C H
CH
Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Ridnour
L A
LA
Cheng
R Y S
RY
Sparatore
A
A
Del Soldato
P
P
Moody
T W
TW
Vitek
M P
MP
Roberts
D D
DD
Wink
D A
DA
D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010766:Phosphorylation; D054648:Protein Phosphatase 2 / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*
D016588:Anticarcinogenic Agents; D051057:Proto-Oncogene Proteins c-akt; D054648:Protein Phosphatase 2
Cell Cycle. 2008 Oct;7(19):2991-6
18818526
Mol Cell Biol. 2002 Apr;22(7):2375-87
11884620
J Biol Chem. 2006 Oct 13;281(41):30503-11
16895907
Biochim Biophys Acta. 2009 Jan;1795(1):1-15
18588945
Cancer Metastasis Rev. 2008 Jun;27(2):147-58
18246411
Cancer Metastasis Rev. 2003 Dec;22(4):375-84
12884912
J Exp Med. 2007 Oct 1;204(10):2397-405
17875674
Cell. 2007 Jun 1;129(5):969-82
17540176
Cancer Metastasis Rev. 2008 Jun;27(2):159-68
18213449
Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5699-704
8650155
Microvasc Res. 2006 May;71(3):152-62
16650878
J Biol Chem. 2003 Mar 7;278(10):8135-45
12506115
Mol Cell Biol. 2006 Apr;26(7):2832-44
16537924
Nat Med. 2002 Oct;8(10):1153-60
12244302
Science. 1992 Aug 28;257(5074):1261-4
1325671
Cancer Lett. 2005 Jun 28;224(2):171-84
15914268
J Biol Chem. 2007 Sep 14;282(37):26971-26980
17635907
Br J Pharmacol. 2007 May;151(1):63-72
17351657
J Biol Chem. 2005 Dec 9;280(49):40406-16
16221682
J Natl Cancer Inst. 2002 Jul 3;94(13):1001-9
12096085
Oncogene. 2006 Jun 1;25(23):3237-46
16407822
Biochem Pharmacol. 1998 May 15;55(10):1585-90
9633994
J Biol Chem. 2004 Mar 5;279(10):8919-29
14688281
Hepatology. 2007 Sep;46(3):730-9
17668885
Biochemistry. 1995 Feb 14;34(6):1988-96
7531497
Oncogene. 2008 Sep 18;27(41):5497-510
18794884
Free Radic Biol Med. 2007 Mar 1;42(5):706-19
17291994
Mol Cancer Ther. 2008 Nov;7(11):3470-9
19001432
Br J Pharmacol. 2003 Apr;138(7):1303-12
12711631
Mol Cell Biol. 2004 Oct;24(19):8778-89
15367694
Cell. 2008 Apr 4;133(1):154-63
18394995
Curr Cancer Drug Targets. 2008 May;8(3):187-98
18473732
Biochem J. 2001 Feb 1;353(Pt 3):417-39
11171037
Mol Pharmacol. 2006 Jul;70(1):41-50
16571654
Anticancer Res. 2007 Sep-Oct;27(5A):3147-62
17970056
Am J Med Sci. 1999 Sep;318(3):146-51
10487404
J Pharmacol Exp Ther. 2002 Jul;302(1):111-8
12065707
Circulation. 2008 Jan 15;117(2):231-41
18195184
Cell Signal. 2002 Mar;14(3):231-8
11812651
Oncogene. 2007 Feb 26;26(9):1338-45
17322919
Mutat Res. 2001 Sep 1;480-481:305-15
11506823
Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10832-7
10995457
J Biol Chem. 2007 Feb 23;282(8):5468-77
17200115
Cardiovasc Res. 2007 Oct 1;76(1):29-40
17631873
Mol Pharmacol. 2006 Oct;70(4):1298-306
16822929
J Cell Physiol. 2001 Oct;189(1):1-13
11573199
Int J Biochem Cell Biol. 2006;38(9):1510-7
16697692